Mandate

Vinge advises EQT in connection with sale of Swedegas

March 23, 2015

Vinge advises EQT Infrastructure in connection with the sale of Swedegas to a consortium of Enagás Internacional S.L.U., part of Spain’s leading natural gas transmission company Enagás S.A., and Fluxys Europe B.V., part of the Belgium-based natural gas infrastructure group Fluxys SA. Swedegas owns and operates Sweden’s entire gas transmission network, extending from Dragör in Denmark to Stenungsund in Sweden. The transaction is expected to close in mid-April.

Vinge’s team consists of responsible partner Daniel Rosvall together with Matthias Pannier and Oscar Rydén (corporate), Carl Johan af Petersens, Johan Cederblad and Helena Wanhainen (regulatory).

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024